Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marvin Lawrence

Gastroenterology Laurel, MD Medical Doctor

NPI 1699770255 CMS profile 31285

7350 Van Dusen Rd, Ste 210, Laurel, MD 20707

Open in the dashboard

General payments

$4,655

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marvin Lawrence of Laurel, MD is reported in the CMS Open Payments database as having received $4,655 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,618 76
2024 General $1,464 60
2023 General $697 33
2022 General $179 9
2021 General $308 16
2020 General $144 7
2019 General $245 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marvin Lawrence
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Marvin Lawrence were reported at $1,618. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Marvin Lawrence Gastroenterology median Middle half National median
2019 $245 $417 $126–$1,100 $163
2020 $144 $224 $74–$624 $114
2021 $308 $352 $106–$1,054 $132
2022 $179 $448 $129–$1,270 $149
2023 $697 $533 $150–$1,390 $160
2024 $1,464 $605 $160–$1,606 $164
2025 $1,618 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $905 43 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $424 20 payments
  3. Pfizer Inc. $400 18 payments
  4. Gilead Sciences, Inc. $311 12 payments
  5. Janssen Biotech, Inc. $306 13 payments
  6. Madrigal Pharmaceuticals $296 13 payments
  7. Regeneron Healthcare Solutions, Inc. $262 14 payments
  8. Genzyme Corporation $262 10 payments
  9. Celgene Corporation $237 13 payments
  10. Ironwood Pharmaceuticals, Inc $123 7 payments
  11. Other $1,130 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,593 212 payments
  2. Education $63 4 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $651 28 payments
  2. SKYRIZI Immunology $338 20 payments
  3. XELJANZ $332 15 payments
  4. VELSIPITY $315 14 payments
  5. ENTYVIO $274 11 payments
  6. DUPIXENT Immunology $262 10 payments
  7. ZEPOSIA $237 13 payments
  8. DUPIXENT Inflammation And Immunology $222 12 payments
  9. REZDIFFRA $199 10 payments
  10. SKYRIZI Immunology $178 11 payments
  11. Other $2,398 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

519

Median for Gastroenterology: 569

Drug cost

$82,340

Median for Gastroenterology: $104,976

Branded share of claims

27.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 60 $56,071
Mesalamine Generic 19 $7,022
Esomeprazole Magnesium Generic 73 $4,755
Dexlansoprazole Dr Dexlansoprazole Brand 18 $4,503
Pantoprazole Sodium Generic 245 $3,884
Azathioprine Generic 11 $2,713
Cholestyramine Light Cholestyramine Brand 21 $2,271
Dicyclomine Hcl Generic 19 $290
Ondansetron Odt Ondansetron Brand 11 $252
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 17 $234

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$89,951

Medicare's payments for the services billed

Medicare patients

302

Average age 72

Services billed

1,257

176 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 37%
Ischemic heart disease 23%
Chronic kidney disease 18%
Osteoporosis 15%
Cancer 14%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $228
$228 — —
SKYRIZI
  • AbbVie, Inc. $125
$125 — —
STELARA
  • Janssen Biotech, Inc. $111
$111 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $105
$105 — —
ZEPOSIA
  • Celgene Corporation $103
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record